ADMET and DMPK

Scope & Guideline

Elevating knowledge in ADMET and DMPK for a safer tomorrow.

Introduction

Immerse yourself in the scholarly insights of ADMET and DMPK with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN1848-7718
PublisherIAPC PUBLISHING
Support Open AccessYes
CountryCroatia
TypeJournal
Convergefrom 2013 to 2024
AbbreviationADMET DMPK / ADMET DMPK
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressS ALICA 4, ZAGREB HR-10000, CROATIA

Aims and Scopes

The journal 'ADMET and DMPK' focuses on the intersection of drug absorption, distribution, metabolism, excretion, and toxicity (ADMET) alongside drug metabolism and pharmacokinetics (DMPK). It serves as a platform for researchers to publish studies that contribute to the understanding of how drugs behave in biological systems, their efficacy, and safety profiles.
  1. ADMET Profiling:
    Research focusing on the absorption, distribution, metabolism, excretion, and toxicity of drugs, providing insights into their pharmacological behavior and safety.
  2. Drug Formulation and Delivery Systems:
    Studies on the development and optimization of drug delivery systems, including nanomaterials and liposomes, aimed at enhancing drug efficacy and bioavailability.
  3. Electrochemical Sensing and Biosensors:
    Innovative methodologies involving electrochemical sensors for detecting drug compounds and biomarkers, which are crucial for pharmacokinetic studies and therapeutic monitoring.
  4. Pharmacokinetics and Modeling:
    Research involving the modeling of drug pharmacokinetics, including novel approaches to predict drug behavior in vivo, which is essential for drug development.
  5. Nanotechnology in Drug Development:
    Exploration of nanotechnology applications in drug formulation, delivery, and diagnostics, highlighting the transformative potential of nanomaterials in enhancing therapeutic outcomes.
The journal 'ADMET and DMPK' has seen a rise in specific themes that reflect current trends in drug development and delivery. These emerging areas indicate the journal's adaptability to the evolving landscape of pharmaceutical research.
  1. Nanomaterials and Drug Delivery Innovations:
    There is an increasing focus on the application of nanomaterials for drug delivery, enhancing bioavailability, and overcoming biological barriers, which is crucial for developing effective therapies.
  2. Electrochemical Biosensors for Biomarker Detection:
    The trend towards using advanced electrochemical methods for detecting biomarkers and drugs highlights the importance of rapid and sensitive diagnostic tools in pharmacokinetics.
  3. Sustainable and Green Chemistry Approaches:
    Research emphasizing environmentally friendly synthesis methods for drug compounds and materials is gaining traction, reflecting a broader commitment to sustainability in pharmaceutical sciences.
  4. Advanced In Vitro Models for Drug Testing:
    The emergence of sophisticated in vitro models, including 3D cell cultures and organ-on-a-chip systems, underscores a shift towards more predictive and ethical approaches in drug testing.
  5. Personalized Medicine and Pharmacogenomics:
    An increasing interest in the interplay between genetics and drug response is evident, indicating a trend towards personalized medicine that tailors treatments based on individual genetic profiles.

Declining or Waning

While 'ADMET and DMPK' continues to advance in various areas, certain themes seem to be losing prominence in recent publications. This shift may reflect evolving research priorities or emerging technologies overshadowing older methodologies.
  1. Traditional Pharmaceutical Formulations:
    Research focusing on conventional drug formulation techniques is becoming less frequent as new technologies, particularly nanotechnology and advanced delivery systems, gain traction.
  2. Basic Pharmacological Studies:
    Studies that solely focus on basic pharmacological effects without integrating ADMET or DMPK perspectives are declining, as the journal emphasizes comprehensive approaches that include these critical factors.
  3. Animal Studies in Drug Development:
    There is a noticeable decrease in studies relying solely on animal models for drug testing, as the field moves towards more ethical and predictive in vitro models, including organ-on-a-chip technologies.

Similar Journals

AAPS Journal

Elevating Standards in Pharmaceutical Research and Methodologies.
Publisher: SPRINGERISSN: 1550-7416Frequency: 1 issue/year

AAPS Journal, published by Springer in the United States, is a leading peer-reviewed journal dedicated to the advancement of research in the field of Pharmaceutical Sciences. With an impressive Q1 rank in its category and a position within the 81st percentile of Scopus rankings, it serves as a vital resource for researchers and professionals seeking to disseminate impactful findings and innovative methodologies. The journal publishes high-quality original research, review articles, and technical reports aimed at addressing the multifaceted challenges in pharmacology, toxicology, and pharmaceutics. Operating under an Open Access model, AAPS Journal ensures broad dissemination of knowledge, contributing to the enhanced visibility and accessibility of research outputs. With a publication window spanning from 1999 to 2024, it continues to shape the future of pharmaceutical research and its applications. Researchers, students, and industry professionals will find a valuable repository of cutting-edge knowledge in this esteemed journal.

Journal of Reports in Pharmaceutical Sciences

Empowering Researchers with Cutting-Edge Findings.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2322-1232Frequency: 2 issues/year

Journal of Reports in Pharmaceutical Sciences is a pivotal publication in the realm of pharmaceutical research, disseminating innovative findings that cater to the evolving landscape of pharmacology, toxicology, and biomedical engineering. Published by Wolters Kluwer Medknow Publications, the journal serves as a bridge for scholars and practitioners aiming to enhance their understanding of drug development, therapeutic advances, and biopharmaceutical technologies. With an ISSN of 2322-1232 and E-ISSN 2322-5106, it has established its relevance from 2012 to 2022, occupying notable quartile rankings, including Q3 in Pharmacology, Toxicology, and Pharmaceutics. Despite being categorized in Q4 in some areas, the journal's commitment to quality research ensures it remains a respected platform for disseminating significant insights. Researchers, professionals, and students alike will find this journal an indispensable resource for staying updated on critical advancements in pharmaceutical sciences, making it a go-to source for impactful studies that shape industry practices and academic inquiries.

Clinical Pharmacology in Drug Development

Innovating therapeutics through rigorous research.
Publisher: WILEYISSN: 2160-7648Frequency: 6 issues/year

Clinical Pharmacology in Drug Development, published by WILEY, is a distinguished journal dedicated to advancing the field of pharmaceutical science and drug development. With a strong commitment to disseminating cutting-edge research, this journal serves as a crucial platform for professionals, researchers, and students aiming to enhance their understanding of pharmacological principles and innovations in medical therapeutics. Since its inception in 2012, the journal has consistently maintained a noteworthy presence in the academic community, currently achieving a Q2 ranking in both Pharmaceutical Science and Medical Pharmacology categories as of 2023. Although the journal operates under a subscription model, it is highly regarded for its rigorous peer-reviewed publications, offering insights into drug efficacy, safety, and regulatory challenges. Positioned at the intersection of clinical practices and pharmaceutical advancements, Clinical Pharmacology in Drug Development plays an essential role in bridging the gap between scientific research and real-world application, ensuring that the latest therapeutic strategies are optimized for patient care.

Pharmaceutical Sciences

Pioneering research at the intersection of science and health.
Publisher: TABRIZ UNIV MEDICAL SCIENCES, FAC PHARMACYISSN: 1735-403XFrequency: 4 issues/year

Pharmaceutical Sciences, an esteemed journal published by Tabriz University of Medical Sciences, Faculty of Pharmacy, serves as a crucial platform for the dissemination of pioneering research in the fields of pharmaceutical science, pharmacology, and toxicology. With an impact factor reflective of its substantial contribution to the scientific community, this open access journal has been accessible since 2012, ensuring that researchers, professionals, and students worldwide can engage with its rich content. Located in Iran, it has continually evolved, covering research from 2009 to 2024, and boasts impressive rankings in multiple Scopus categories, including Q3 in Pharmaceutical Science and Q2 in Pharmacology, Toxicology and Pharmaceutics. By bridging gaps between scientific inquiry and practical applications, Pharmaceutical Sciences is dedicated to advancing pharmaceutical knowledge and promoting innovative practices that address significant health challenges.

AAPS PHARMSCITECH

Empowering Researchers to Shape the Future of Pharmacy
Publisher: SPRINGERISSN: 1530-9932Frequency: 1 issue/year

AAPS PHARMSCITECH is a prestigious peer-reviewed journal published by Springer, focusing on the dynamic field of pharmaceutical sciences and technology. With an ISSN of 1530-9932, it provides a vital platform for disseminating cutting-edge research that spans key areas including drug discovery, pharmacology, toxicology, and ecological impacts of pharmaceuticals. The journal is recognized for its rigorous scientific contributions, currently holding a commendable Q2 quartile ranking across several relevant categories, including Agronomy and Crop Science, Aquatic Science, and Medicine in 2023. Notably, it ranks 43rd out of 183 in the Scopus Pharmacology, Toxicology, and Pharmaceutics category, placing it in the 76th percentile of its field. Aiming to foster innovation and collaboration among researchers, professionals, and students, AAPS PHARMSCITECH is committed to advancing scientific knowledge and addressing contemporary challenges in pharmaceutical sciences. The journal offers various access options to ensure wide dissemination of research findings, making it an essential resource for those dedicated to enhancing public health through pharmaceutical advancements.

Journal of Pharmaceutical Analysis

Connecting researchers to shape the future of drug analysis.
Publisher: ELSEVIERISSN: 2095-1779Frequency: 12 issues/year

Journal of Pharmaceutical Analysis is a premier open-access journal published by ELSEVIER, dedicated to advancing the field of pharmaceutical sciences. Since its inception in 2011, this journal has become a vital resource for researchers, professionals, and students, with a focus on analytical chemistry, drug discovery, and electrochemistry, among other subjects. With an impressive impact factor reflected in its Q1 ranking across multiple categories such as Analytical Chemistry and Drug Discovery in 2023, it maintains a high standard in the dissemination of innovative research. The journal not only facilitates the sharing of significant findings but also promotes collaboration and discussion within the community, making a notable impact globally. Articles published in the Journal of Pharmaceutical Analysis are easily accessible under an open-access model, ensuring that cutting-edge research reaches a diverse audience and enhances knowledge in this critical field. As it continues to converge research from 2011 to 2024, the journal remains a cornerstone in the study of pharmaceutical evaluation, analytical methods, and their applications.

CANCER CHEMOTHERAPY AND PHARMACOLOGY

Exploring breakthroughs in cancer therapy and drug development.
Publisher: SPRINGERISSN: 0344-5704Frequency: 12 issues/year

Cancer Chemotherapy and Pharmacology, published by Springer, is a leading peer-reviewed journal that plays a crucial role in the field of cancer research and drug therapy. With an ISSN of 0344-5704 and an E-ISSN of 1432-0843, this journal has been a cornerstone of oncology and pharmacology research since its inception in 1978, with continued relevance through to 2024. The journal holds a commendable Q2 ranking in categories such as Cancer Research, Oncology, and Pharmacology (medical), while achieving an elite Q1 status in Toxicology, reflecting its high-impact contributions to the scientific community. Researchers and professionals benefit from access to cutting-edge studies, insightful reviews, and innovative methodologies, making it a vital resource for anyone working at the intersection of pharmacology and oncology. Although not an open-access journal, Cancer Chemotherapy and Pharmacology remains highly accessible through institutional subscriptions, ensuring it reaches a broad audience dedicated to advancing cancer treatment and patient care.

CURRENT DRUG METABOLISM

Pioneering Insights for Clinical Biochemistry
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1389-2002Frequency: 14 issues/year

CURRENT DRUG METABOLISM, published by Bentham Science Publishers Ltd, serves as a pivotal resource in the fields of Clinical Biochemistry and Pharmacology. With an ISSN of 1389-2002 and an E-ISSN of 1875-5453, this journal has carved a niche since its inception in 2000, offering in-depth research and reviews that bridge the gap between drug metabolism and its clinical applications. The journal finds itself positioned in the third quartile (Q3) for both Clinical Biochemistry and Pharmacology as of 2023, reflecting its significance within these scientific sectors, with Scopus rankings showcasing its role in advancing knowledge—rank #167 in Pharmacology and #66 in Clinical Biochemistry. Researchers and industry professionals are encouraged to contribute their findings, fostering a diverse platform that informs and inspires innovations in drug development and safety. While CURRENT DRUG METABOLISM operates under a traditional subscription model without open access, its rigorous peer-review process ensures the quality and integrity of the published work, making it indispensable for anyone engaged in drug research and biochemistry.

DRUG METABOLISM REVIEWS

Unraveling the complexities of drug interactions.
Publisher: TAYLOR & FRANCIS LTDISSN: 0360-2532Frequency: 4 issues/year

Drug Metabolism Reviews is a premier journal dedicated to the dissemination of scientific research and reviews in the field of pharmacology, toxicology, and pharmaceutics, published by Taylor & Francis Ltd. With its inception dating back to 1972, this journal has consistently provided an authoritative platform for scholars and professionals from diverse disciplines to explore the intricate mechanisms of drug metabolism and their implications for therapeutic applications. The journal enjoys commendable rankings, placing in the Q2 quartile for Pharmacology (medical) and the Q1 quartile in the miscellaneous subfield, signaling its significant impact within the community. Notably, it is recognized within the top 96th percentile in General Pharmacology, Toxicology and Pharmaceutics, affirming its esteemed position among academic publications. Although it operates under a subscription model, Drug Metabolism Reviews remains an essential resource for researchers, professionals, and students seeking to deepen their understanding of drug interactions, safety, and efficacy. The insights shared within its pages contribute vital knowledge to the global discourse on drug development and personalized medicine.

Chemical Biology & Drug Design

Fostering breakthroughs in molecular medicine and drug design.
Publisher: WILEYISSN: 1747-0277Frequency: 12 issues/year

Chemical Biology & Drug Design, an esteemed publication by WILEY, serves as a vital platform for the dissemination of pioneering research in the interdisciplinary fields of biochemistry, drug discovery, molecular medicine, organic chemistry, and pharmacology. With a dedicated commitment to advancing the understanding of chemical interactions and drug development, this journal not only fosters innovation but also bridges the gap between theoretical research and practical applications. It boasts an impressive impact factor and is recognized in the 2023 category quartiles as Q3 in Biochemistry and Molecular Medicine, and Q2 in Drug Discovery, Organic Chemistry, and Pharmacology, indicating its relevance and influence in these crucial areas. The journal’s rankings across various Scopus categories further solidify its position as a reputable resource for researchers, professionals, and students striving to stay at the forefront of medicinal chemistry and drug design. While primarily traditional access-based, the journal's evolving scope from 2006 to 2024 ensures an ongoing contribution to essential scientific dialogue, making it an indispensable read for those committed to advancing health sciences.